ALS: when time pressure meets the hardest evidence bar

An ALS diagnosis compresses every decision. Whatever might help must be considered now — which clinics understand better than anyone. Families sell houses for infusion courses; the disease's cruelty does the marketing. This profile exists to protect both hope and resources.

What the data says for this situation

ALS has serious cell-therapy research behind it: 29 MSC and 11 HSCT-family studies in our snapshot, including well-run programmes (neurotrophic-factor-secreting MSCs among them) that reached late-phase trials — and missed their primary endpoints. Regulators reviewed and declined the flagship product. Research continues in subgroups and combinations, but today no cell therapy has demonstrated slowed progression in controlled trials, and none is approved anywhere with credible oversight.

Every legitimate avenue is a registered trial; several actively recruit. The commercial offers surrounding this disease — repeated “boosters”, intrathecal packages abroad — monetise urgency against that backdrop.

Questions worth asking any provider

1. Registered trial with a number I can verify — or a paid protocol?
2. What did the cited study measure on ALSFRS-R, and did it hit its endpoint?
3. How many infusions before this clinic calls it non-response?
4. Does travel and treatment burden cost me function time the trial data cannot repay?

Red flags specific to this situation

• Progression-slowing percentages citing failed-endpoint trials
• Multi-course packages with per-course discounts
• Clinics discouraging registered-trial participation as 'placebo risk'

Cost context

Commercial ALS packages abroad run €15,000–€50,000 across courses. Registered trials charge nothing and represent the only route with scientific oversight.

FAQ

Has any stem cell therapy slowed ALS?

Controlled trials, including late-phase programmes, have not met progression endpoints; regulators declined approval.

Should trials still be considered?

Yes — they are the legitimate access path and several recruit; verification matters more here than anywhere.

→ Build questions for a specific provider · → Cost calculator

Interactive/editorial page by the StemCellAtlas research team. Where registry or literature counts appear, they use the dated 2026-08-29 snapshot. Browser-only tools do not send or store answers. Page generated 2026-08-29. See our editorial standards.